Efficacy of Digital Speech Therapy for Poststroke Dysarthria: Randomized Noninferiority Trial - Scorecard - MDSpire

Efficacy of Digital Speech Therapy for Poststroke Dysarthria: Randomized Noninferiority Trial

  • By

  • Yuyoung Kim

  • Minjung Kim

  • Saebyeol Kim

  • Jinwoo Kim

  • Joon-Ho Shin

  • Yoonkyung Chang

  • Ji Young Na

  • JungWan Kim

  • Tae-Jin Song

  • May 18, 2026

  • 0 min

Share

Clinical Scorecard: Effectiveness of Digital Speech Therapy in Treating Dysarthria Following Stroke: A Randomized Noninferiority Study

At a Glance

CategoryDetail
ConditionPoststroke Dysarthria
Key MechanismsImpairments in articulation, phonation, prosody, resonance, and respiration affecting speech intelligibility.
Target PopulationAdults aged 19 years or older with dysarthria caused by first-ever stroke.
Care SettingMulticenter stroke centers in South Korea.

Key Highlights

  • 22%-60% of stroke survivors experience motor speech disorders, including dysarthria.
  • Digital speech therapy offers an alternative to conventional face-to-face therapy.
  • The study compares smartphone-based digital therapy to workbook-based therapy.
  • Participants included adults with mild-to-moderate or severe dysarthria.
  • The trial aims to evaluate speech intelligibility and broader therapeutic impacts.

Guideline-Based Recommendations

Diagnosis

  • Confirm dysarthria diagnosis via stroke specialist assessment.
  • Use the National Institutes of Health Stroke Scale for severity scoring.

Management

  • Implement behavioral speech therapy as the standard treatment.
  • Consider digital speech therapy for improved access and adherence.

Monitoring & Follow-up

  • Assess speech intelligibility and patient-reported outcomes regularly.

Risks

  • Exclude patients with aphasia or other neurological conditions affecting speech.

Patient & Prescribing Data

Adults with first-ever stroke and confirmed dysarthria.

Digital therapy can enhance practice frequency and reduce clinician dependency.

Clinical Best Practices

  • Ensure neurologically stable condition before therapy initiation.
  • Facilitate access to therapy for patients with geographic or financial barriers.

Related Resources & Content

Original Source(s)

Related Content